Multidisciplinary tumor board analysis: validation study of a central tool in tumor centers.
Left-truncated survival times
Multiple myeloma (MM)
Tumor boards (TBs)
Validation assessment
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
19
07
2022
accepted:
10
11
2022
pubmed:
5
12
2022
medline:
4
3
2023
entrez:
4
12
2022
Statut:
ppublish
Résumé
The established standard to ensure state-of-the-art cancer treatment is through multidisciplinary tumor boards (TBs), although resource- and time-intensive. In this validation study, the multiple myeloma (MM)-TB was reexamined, aiming to validate our previous (2012-2014) results, now using the TB data from March 2020 to February 2021. We assessed MM-TB protocols, physicians' documentation, patient, disease, remission status, progression-free survival (PFS), and overall survival (OS) as left-truncated survival times. Moreover, TB-adherence, level of evidence according to grade criteria, time requirements, study inclusion rates, and referral satisfaction were determined. Within a 1-year period, 312 discussed patients were documented in 439 TB protocols. Patient and disease characteristics were typical for comprehensive cancer centers. The percentages of patients discussed at initial diagnosis (ID), with disease recurrence or in need of interdisciplinary advice, were 39%, 28%, and 33%, respectively. Reasons for the MM-TB presentation were therapeutic challenges in 80% or staging/ID-defining questions in 20%. The numbers of presentations were mostly one in 73%, two in 20%, and three or more in 7%. The TB adherence rate was 93%. Reasons for non-adherence were related to patients' decisions or challenging inclusion criteria for clinical trials. Additionally, we demonstrate that with the initiation of TBs, that the number of interdisciplinarily discussed patients increased, that TB-questions involve advice on the best treatment, and that levels of compliance and evidence can be as high as ≥ 90%. Advantages of TBs are that they may also improve patients', referrers', and physicians' satisfaction, inclusion into clinical trials, and advance interdisciplinary projects, thereby encouraging cancer specialists to engage in them.
Identifiants
pubmed: 36464695
doi: 10.1007/s00277-022-05051-y
pii: 10.1007/s00277-022-05051-y
pmc: PMC9734518
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-611Informations de copyright
© 2022. The Author(s).
Références
Engelhardt M, Selder R, Pandurevic M, Möller M, Ihorst G, Waldschmidt J et al (1946) Multidisciplinary tumor boards: facts and satisfaction analysis of an indispensable comprehensive cancer center instrument. Dtsch Med Wochenschr 2017(142):e51-60. https://doi.org/10.1055/s-0043-100054
doi: 10.1055/s-0043-100054
Barthélémy P, Heitz D, Mathelin C, Polesi H, Asmane I, Litique V et al (2011) Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol 79:196–204. https://doi.org/10.1016/j.critrevonc.2010.06.005
doi: 10.1016/j.critrevonc.2010.06.005
pubmed: 20655243
Kesson EM, Allardice GM, George WD, Burns HJG, Morrison DS (2012) Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ 344:e2718. https://doi.org/10.1136/bmj.e2718
doi: 10.1136/bmj.e2718
pubmed: 22539013
pmcid: 3339875
Kreyer J, Ranft A, Timmermann B, Juergens H, Jung S, Wiebe K et al (2018) Impact of the Interdisciplinary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy. Pediatr Blood Cancer 65:e27384. https://doi.org/10.1002/pbc.27384
doi: 10.1002/pbc.27384
pubmed: 30084137
Peckham J, Mott-Coles S (2018) Interprofessional Lung Cancer Tumor Board: the role of the oncology nurse navigator in improving adherence to national guidelines and streamlining patient care. Clin J Oncol Nurs 22:656–662. https://doi.org/10.1188/18.CJON.656-662
doi: 10.1188/18.CJON.656-662
pubmed: 30452006
Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW et al (2020) Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective “Deutsche Studiengruppe MM” (DSMM) and “European Myeloma Network” (EMN) analysis. Leuk Lymphoma 61:875–886. https://doi.org/10.1080/10428194.2019.1695051
doi: 10.1080/10428194.2019.1695051
pubmed: 31779510
van de Donk NWCJ, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet Lond Engl 397:410–427. https://doi.org/10.1016/S0140-6736(21)00135-5
doi: 10.1016/S0140-6736(21)00135-5
Engelhardt M, Ihorst G, Duque-Afonso J, Wedding U, Spät-Schwalbe E, Goede V et al (2020) Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. Haematologica 105:1183–1188. https://doi.org/10.3324/haematol.2019.242958
doi: 10.3324/haematol.2019.242958
pubmed: 32241848
pmcid: 7193478
Engelhardt M, Ihorst G, Schumacher M, Rassner M, Gengenbach L, Möller M et al (2021) Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures. BMC Cancer 21:173. https://doi.org/10.1186/s12885-021-07878-6
doi: 10.1186/s12885-021-07878-6
pubmed: 33596881
pmcid: 7891134
Gengenbach L, Graziani G, Reinhardt H, Rösner A, Braun M, Möller M-D et al (2021) Choosing the right therapy for patients with relapsed/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors. Cancers 13:4320. https://doi.org/10.3390/cancers13174320
doi: 10.3390/cancers13174320
pubmed: 34503130
pmcid: 8430818
Ahlbrandt J, Lablans M, Glocker K, Stahl-Toyota S, Maier-Hein K, Maier-Hein L et al (2020) Modern information technology for cancer research: what’s in IT for me? An overview of technologies and approaches. Oncology 2018:1–7. https://doi.org/10.1159/000493638
doi: 10.1159/000493638
Anderson JR, Cain KC, Gelber RD (2008) Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol Off J Am Soc Clin Oncol 26:3913–3915. https://doi.org/10.1200/JCO.2008.16.1000
doi: 10.1200/JCO.2008.16.1000
Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim K-H, Mullady DK et al (2017) Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. HPB 19:133–139. https://doi.org/10.1016/j.hpb.2016.11.002
doi: 10.1016/j.hpb.2016.11.002
pubmed: 27916436
El Saghir NS, Keating NL, Carlson RW, Khoury KE, Fallowfield L (2014) Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 2014:e461-466
doi: 10.14694/EdBook_AM.2014.34.e461
Kehl KL, Landrum MB, Kahn KL, Gray SW, Chen AB, Keating NL (2015) Tumor board participation among physicians caring for patients with lung or colorectal cancer. J Oncol Pract 11:e267-278. https://doi.org/10.1200/JOP.2015.003673
doi: 10.1200/JOP.2015.003673
pubmed: 25922221
pmcid: 4438111
Lamb BW, Brown KF, Nagpal K, Vincent C, Green JSA, Sevdalis N (2011) Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol 18:2116–2125. https://doi.org/10.1245/s10434-011-1675-6
doi: 10.1245/s10434-011-1675-6
pubmed: 21442345
Lee MC, Bhati RS, von Rottenthaler EE, Reagan AM, Karver SB, Reich RR et al (2013) Therapy choices and quality of life in young breast cancer survivors: a short-term follow-up. Am J Surg 206:625–631. https://doi.org/10.1016/j.amjsurg.2013.08.003
doi: 10.1016/j.amjsurg.2013.08.003
pubmed: 24016705
pmcid: 4503361
Engelhardt M, Shoumariyeh K, Rösner A, Ihorst G, Biavasco F, Meckel K et al (2020) Clinical characteristics and outcome of multiple myeloma patients with concomitant Covid-19 at Comprehensive Cancer Centers in Germany. Haematologica 105(12):2872–2878. https://doi.org/10.3324/haematol.2020.262758
Shoumariyeh K, Biavasco F, Ihorst G, Rieg S, Nieters A, Kern WV et al (2020) Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. Cancer Med 9:8412–8422. https://doi.org/10.1002/cam4.3460
doi: 10.1002/cam4.3460
pubmed: 32931637
pmcid: 7666742
Piechotta V, Skoetz N, Engelhardt M, Einsele H, Goldschmidt H, Scheid C (2022) Clinical practice guideline: patients with multiple myeloma or monoclonal gammopathy of undetermined significance–diagnosis, treatment, and follow up. Dtsch Arzteblatt Int 119(14):253–260. https://doi.org/10.3238/arztebl.m2022.0149
Ihorst G, Waldschmidt J, Schumacher M, Wäsch R, Engelhardt M (2015) Analysis of survival by tumor response: have we learnt any better? Ann Hematol 94:1615–1616. https://doi.org/10.1007/s00277-015-2426-8
doi: 10.1007/s00277-015-2426-8
pubmed: 26099841
Dold SM, Möller M-D, Ihorst G, Langer C, Pönisch W, Mügge L-O et al (2021) Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica 106:875–880. https://doi.org/10.3324/haematol.2020.254235
doi: 10.3324/haematol.2020.254235
pubmed: 32414853
Engelhardt M, Mertelsmann R, Duyster J (2020) Das Blaue Buch. 6.Auflage. Springer
Berger D, Mertelsmann R (2017) Das Rote Buch. 6.Auflage. Ecomed
Freytag M, Herrlinger U, Hauser S, Bauernfeind FG, Gonzalez-Carmona MA, Landsberg J et al (2020) Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. BMC Cancer 20:355. https://doi.org/10.1186/s12885-020-06809-1
doi: 10.1186/s12885-020-06809-1
pubmed: 32345242
pmcid: 7189747
Engelhardt M, Herget GW, Graziani G, Ihorst G, Reinhardt H, Ajayi S et al (2018) Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. Haematologica 103:755–758. https://doi.org/10.3324/haematol.2018.188516
doi: 10.3324/haematol.2018.188516
pubmed: 29712821
pmcid: 5927973
Gengenbach L, Reinhardt H, Ihorst G, Ajayi S, Dold SM, Köhler M et al (2018) Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials. Leuk Lymphoma 59:2692–2699. https://doi.org/10.1080/10428194.2018.1448084
doi: 10.1080/10428194.2018.1448084
pubmed: 29569975
Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G et al (2014) European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99:232–242. https://doi.org/10.3324/haematol.2013.099358
doi: 10.3324/haematol.2013.099358
pubmed: 24497560
pmcid: 3912952
Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW et al (2018) From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica 103:197–211. https://doi.org/10.3324/haematol.2017.174573
doi: 10.3324/haematol.2017.174573
pubmed: 29217780
pmcid: 5792264